3 Stocks Underperforming Today In The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,877 as of Thursday, June 19, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,663 issues advancing vs. 1,297 declining with 187 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Waters ( WAT), down 1.2%, and Agilent Technologies ( A), down 0.8%. Top gainers within the industry include Smith & Nephew ( SNN), up 1.2%, Stryker Corporation ( SYK), up 1.2%, Covidien ( COV), up 0.7% and Abbott Laboratories ( ABT), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Opko Health ( OPK) is one of the companies pushing the Health Services industry lower today. As of noon trading, Opko Health is down $0.20 (-2.1%) to $9.20 on average volume. Thus far, 902,459 shares of Opko Health exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $9.19-$9.34 after having opened the day at $9.29 as compared to the previous trading day's close of $9.40.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.9 billion and is part of the health care sector. Shares are up 11.4% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Grifols ( GRFS) is down $0.33 (-0.7%) to $45.41 on light volume. Thus far, 179,570 shares of Grifols exchanged hands as compared to its average daily volume of 667,000 shares. The stock has ranged in price between $45.20-$45.84 after having opened the day at $45.79 as compared to the previous trading day's close of $45.74.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $15.6 billion and is part of the health care sector. Shares are up 25.6% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.65 (-0.5%) to $119.25 on light volume. Thus far, 749,764 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $118.85-$120.40 after having opened the day at $120.00 as compared to the previous trading day's close of $119.90.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. Thermo Fisher Scientific has a market cap of $47.3 billion and is part of the health care sector. Shares are up 7.7% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Thermo Fisher Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Biotech Movers: Paratek, Opko, Endo

Biotech Movers: Paratek, Opko, Endo